SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.79 HKD | +0.56% |
|
-1.10% | -29.80% |
| Jun. 21 | Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial | MT |
| Jun. 21 | Shanghai Fudan Zhangjiang Bio-Pharmaceutical Terminates Libod Marketing Agreement | MT |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.80% | 702M | |
| +8.12% | 72.4B | |
| +15.93% | 8.98B | |
| -24.60% | 4.28B | |
| +15.26% | 4.28B | |
| +28.46% | 4.01B | |
| +6.84% | 2.16B | |
| -35.98% | 1.9B | |
| +7.76% | 1.95B | |
| -47.71% | 1.63B |
- Stock Market
- Equities
- 1349 Stock
- News Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
- Shanghai Fudan-Zhangjiang Admits First Patient in Confirmatory Clinical Trial for Tumor Margin Visualization
